By Julia Karow
Life Technologies said this week that through a collaboration with a sequencing center in Cambridge, UK, it is making its SOLiD platform available to scientists for translational research studies.
Under the collaboration, scientists at the Eastern Sequence and Informatics Hub at Addenbrooke's Hospital in Cambridge will use three SOLiD 3 Plus systems for targeted medical resequencing and whole-transcriptome studies in disease areas such as cancer, diabetes, and neurological disorders.
According to John Todd, a professor at the University of Cambridge and the leader of the sequencing center, "the translation of this information into clinically relevant knowledge will have a direct impact on the treatment of human disease through the development of better diagnostic, prognostic, and therapeutic agents."
The center was established earlier this year with £2.4 million ($4 million) from the UK's Medical Research Council, as well as funding from the University's Clinical School and NIHR Biomedical Research Centre.
Todd told In Sequence in May that the center, which has ongoing collaborations with both Life Technologies and Roche/454 Life Sciences, planned to acquire at least two types of second-generation sequencing systems (see In Sequence 5/19/2009).